Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Has $8.11 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. cut its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 33.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 423,272 shares of the company's stock after selling 209,818 shares during the period. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.53% of Viridian Therapeutics worth $8,114,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in VRDN. Loomis Sayles & Co. L P bought a new position in Viridian Therapeutics during the fourth quarter worth about $26,845,000. Price T Rowe Associates Inc. MD grew its position in shares of Viridian Therapeutics by 2,847.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company's stock worth $25,436,000 after purchasing an additional 1,281,799 shares in the last quarter. Deep Track Capital LP increased its holdings in shares of Viridian Therapeutics by 20.6% during the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock worth $86,701,000 after purchasing an additional 771,796 shares during the period. FMR LLC increased its holdings in shares of Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock worth $227,776,000 after purchasing an additional 698,434 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in shares of Viridian Therapeutics by 155.9% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company's stock valued at $20,850,000 after buying an additional 662,634 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VRDN. Needham & Company LLC reissued a "buy" rating and set a $36.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, May 20th. JMP Securities reduced their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group decreased their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, Royal Bank of Canada reduced their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $36.70.

Viridian Therapeutics Price Performance

Shares of VRDN stock traded down $0.10 on Friday, hitting $13.57. 645,430 shares of the company's stock were exchanged, compared to its average volume of 1,192,233. The company has a 50 day moving average of $13.17 and a 200 day moving average of $16.81. The stock has a market cap of $1.11 billion, a P/E ratio of -3.15 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. The business's revenue for the quarter was up .0% compared to the same quarter last year. On average, equities research analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.